TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06618391
Drug: recombinant human adenovirus type 5
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Study: NCT04939545
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.
Study: NCT06329687
Drug: Tyrvaya Nasal Pump
Normalized name: Tyrvaya Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrvaya Nasal Pump with Silicone Lubricant
Study: NCT05622318
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg/kg by IV on Days +3 and +4.
Study: NCT06078709
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06078709
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05003102
Drug: Fentanyl - PICU Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
Study: NCT05306366
Drug: [11C]-Lu AF90103
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET ligand administrated as a single intravenous bolus injection
Study: NCT06277635
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin is randomly assigned to the participants for 12 weeks during study.
Study: NCT06277635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is randomly assigned to the participants for 12 weeks during study.
Study: NCT04157114
Drug: MAP4343
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Study: NCT04157114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
Study: NCT04731155
Drug: standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard medications was giving to subjects according guidelines
Study: NCT04530058
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day, administered orally or via gastric tube.
Study: NCT05088369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously.
Study: NCT06662526
Drug: Placebo pill plus treatment as usual
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo pill plus treatment as usual by their clinical providers
Study: NCT06102382
Drug: Norepinephrine (0.1)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
Study: NCT06102382
Drug: Norepinephrine (0.075)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
Study: NCT05804045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04729179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
Study: NCT06134193
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
Study: NCT05206955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT04781868
Drug: Multi-nutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
Study: NCT04781868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04660799
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
Study: NCT04660799
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2
Study: NCT06684509
Drug: Atrovastain
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
Study: NCT04768972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by IT bolus injection.
Study: NCT06666166
Drug: SHR-A1811 & Apartinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
Study: NCT04796623
Drug: TQB3616 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
Study: NCT05622058
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
Study: NCT04865744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet is taken after an overnight fast with up to120 ml of water.
Study: NCT04884256
Drug: CBT-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose response study
Study: NCT05052398
Drug: Placebo PSP NEURO SERUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
Study: NCT04780152
Drug: Fluoxetine Tablets
Normalized name: Fluoxetine Tablets
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
Study: NCT05772338
Drug: BNP105 (25 + 25 + 15)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
Study: NCT00001016
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04863339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
Study: NCT06157099
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT06154343
Drug: GQ1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: an antibody drug conjugate
Study: NCT05354102
Drug: BMC128
Approvals — FDA: no, EMA: no, PMDA: no
Description: A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
Study: NCT06322095
Drug: MET inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous MET inhibitor
Study: NCT06322095
Drug: BRAF Inhibito
Normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous BRAF inhibitor
Study: NCT06322095
Drug: MEK Inhibitor
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous MEK Inhibitor
Study: NCT05543109
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mic/kg during induction of anesthesia
Study: NCT06550011
Drug: ABI-110 Low Dose
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose. lower than the safety factor of 10 as recommended by the FDA
Study: NCT06550011
Drug: ABI-110 Medium Dose
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose
Study: NCT06550011
Drug: ABI-110 High Dose
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose
Study: NCT05245916
Drug: IBI397
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Study: NCT04945421
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study: NCT05545800
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
Study: NCT05568121
Drug: L04RD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04RD1
Study: NCT05568121
Drug: L04TD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04TD1
Study: NCT06212648
Drug: SPC1001 Mid1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study: NCT06212648
Drug: SPC4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study: NCT06212648
Drug: SPC4002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study: NCT06212648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study: NCT05579184
Drug: [177Lu]Ludotadipep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Study: NCT00012688
Drug: Doxycycline HCI 10mg po for 2 weeks
Normalized name: Doxycycline for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06482684
Drug: KTE-X19
Approvals — FDA: no, EMA: no, PMDA: no
Description: See description of treatment arms
Study: NCT04982211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules, dosed per participant weight
Study: NCT05468242
Drug: Neoadjuvant chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
Study: NCT04899778
Drug: Oral Contraceptive Pill, norethindrn a-e estradiol-iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT04923113
Drug: Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
Study: NCT06372249
Drug: NOVELOSETM 3490
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble tapioca starch from Ingredion.
Study: NCT06041165
Drug: JS401
Normalized name: Janus Kinase Inhibitor JS401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JS401 by subcutaneous (sc) injections
Study: NCT06041165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active treatment
Study: NCT04984057
Drug: PS is stopped when the pressure is equal between bPDA and aPDA.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
Study: NCT06649136
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison between oral and subcutaneous methotrexate dosis of 25mg
Study: NCT04988971
Drug: a compound glutamine capsule simulated placebo
Normalized name: glutamine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study: NCT06172036
Drug: Adebellizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study: NCT02129751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo arm
Study: NCT06666010
Drug: PEX010-Assisted Therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Study: NCT06666010
Drug: PEX010(01)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Study: NCT06313632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP with matching saline placebo
Study: NCT05036577
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
Study: NCT02414178
Drug: F 18 T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04679012
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT06666959
Drug: Anesthesia Agent
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous anesthetic and inhalation anesthetic
Study: NCT05462340
Drug: [18F]AZAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
Study: NCT06231680
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.
Study: NCT01511822
Drug: Drospirenone Ethinyl estradiol
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
Study: NCT01511822
Drug: Drospirenone Ethinyl estradiol Myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
Study: NCT01511822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05367284
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testogel 16.2 miligrams/ gram (mg/g) gel
Study: NCT04798989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT06621836
Drug: ICPB H
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side
Study: NCT06429345
Drug: Coenzyme Q10 100 Milligrams Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
Study: NCT06429345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
Study: NCT04910685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT05335447
Drug: GLPG3667 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, participants will receive a single oral dose of GLPG3667
Study: NCT05335447
Drug: [14C]-GLPG3667 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
Study: NCT05335447
Drug: [14C]-GLPG3667 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
Study: NCT05051696
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
Study: NCT05202327
Drug: PDC-1421 Capsule
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
Study: NCT05970822
Drug: BC3402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating of BC3402 will be administered IV(intravenous)
Study: NCT05502146
Drug: Noradrenaline Bitartrate
Normalized name: Noradrenaline bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Study: NCT05502146
Drug: Noradrenaline Bitartrate
Normalized name: Noradrenaline bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
Study: NCT06136598
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet to be taken orally as a rescue medication.
Study: NCT00034957
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00611845
Drug: Aprotinin (Trasylol, BAYA0128)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trasylol at either 1,000,000 KIU or 2,000,000 KIU